Inici › Limfoma difús de cèl·lules B grans › Texas › Houston
Assaigs clínics de Limfoma difús de cèl·lules B grans a Houston, TX
17 estudis de Limfoma difús de cèl·lules B grans busquen participants en centres de Houston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
ReclutantFase 2
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ReclutantEstudi observacional
- Texas Children's Hospital, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutantFase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
ReclutantFase 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ReclutantFase 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
ReclutantFase 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
ReclutantFase 1
- Md Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
ReclutantFase 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
ReclutantFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
ReclutantFase 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
ReclutantFase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
ReclutantFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutantFase 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
ReclutantFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Assaigs de Limfoma difús de cèl·lules B grans en altres ciutats
- New York City, NY21 estudis
- Baldwin Park, CA19 estudis
- Chicago, IL18 estudis
- Los Angeles, CA17 estudis
- Boston, MA16 estudis
- Milwaukee, WI16 estudis
- Nashville, TN15 estudis
- Portland, OR15 estudis
- Philadelphia, PA15 estudis
- Durham, NC14 estudis
- Dallas, TX13 estudis
- Seattle, WA12 estudis
Altres estudis a Houston
- Càncer de pulmó de cèl·lules no petites145 estudis
- Càncer de mama126 estudis
- Càncer (tots els tipus)121 estudis
- Càncer metastàtic104 estudis
- Càncer colorrectal102 estudis
- Càncer d'ovari89 estudis
- Leucèmia mieloide aguda85 estudis
- Càncer de pulmó78 estudis
- Càncer de pròstata76 estudis
- Càncer d'endometri68 estudis
- Càncer de pàncrees61 estudis
- Melanoma59 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.